ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company focused on anaphylaxis prevention, announced its participation in two upcoming investor conferences. The company's leadership will present at the Cantor Global Healthcare Conference on September 3, 2025, at 3:55 p.m. ET in New York, and the Stifel Immunology and Inflammation Summit on September 15, 2025, at 12:00 p.m. ET virtually.
Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will represent the company. Live webcasts will be available on the company's website, with replays accessible for 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – SPRY
In the Aug 28 session, SPRY declined 4.32%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in presentations at the Cantor Global Healthcare Conference and the Stifel Immunology and Inflammation Summit in September.
Details outlined below.
Cantor Global Healthcare Conference
Presentation (Fireside Chat): Wednesday, September 3, 2025
Time: 3:55 p.m. ET
Location: New York
A live webcast of the presentation will be available here.
Stifel Immunology and Inflammation Summit
Presentation: Monday, September 15, 2025
Time: 12:00 p.m. ET
Location: Virtual
A live webcast of the presentation will be available here.
To access the live and archived webcasts for the investor conferences, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of each of the webcasts will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668
